ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Clindamycin (topical): Pediatric drug information

Clindamycin (topical): Pediatric drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Clindamycin (topical): Drug information" and "Clindamycin (topical): Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Cleocin;
  • Cleocin-T;
  • Clindacin;
  • Clindacin ETZ;
  • Clindacin Pac [DSC];
  • Clindacin-P;
  • Clindagel;
  • Clindesse;
  • Evoclin [DSC];
  • Xaciato
Brand Names: Canada
  • Clinda-T [DSC];
  • Dalacin T [DSC];
  • Dalacin Vaginal;
  • TARO-Clindamycin
Therapeutic Category
  • Acne Products;
  • Antibiotic, Anaerobic;
  • Antibiotic, Miscellaneous
Dosing: Pediatric
Acne vulgaris

Acne vulgaris: Note: Due to emerging resistance patterns, should not typically be used as monotherapy for the management of acne vulgaris (Ref).

Children ≥7 years and Adolescents: Limited data available in <12 years of age (Ref):

Gel (Clindagel), Foam (Evoclin): Topical: Apply to affected area once daily.

Gel (Cleocin T), pledget, lotion, solution: Topical: Apply a thin film twice daily.

Bacterial vaginosis

Bacterial vaginosis: Note: The 7-day vaginal cream regimen is preferred (Ref).

Cream 2%:

7-day regimen: Cleocin: Children weighing ≥45 kg and Adolescents: Limited data available: Intravaginal: One full applicator (5 g) once daily at bedtime for 7 days (Ref).

1-day regimen: Clindesse: Adolescents: Intravaginal: One full applicator (5 g) once as a single dose (Ref).

Gel 2%: Xaciato: Children ≥12 years and Adolescents: Intravaginal: One full applicator (5 g) once as a single dose.

Suppository: Cleocin: Adolescents: Intravaginal: One ovule (100 mg clindamycin) once daily at bedtime for 3 days.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, no dosage adjustments are required with systemic clindamycin use.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, no dosage adjustments are required with systemic clindamycin use; use caution with severe hepatic impairment.

Dosing: Adult

(For additional information see "Clindamycin (topical): Drug information")

Acne vulgaris

Acne vulgaris:

Note: Use in combination with benzoyl peroxide to reduce the risk for the development of antibiotic resistance (Ref).

Topical:

Gel (Cleocin T, ClindaMax), pledget, lotion, solution: Apply a thin film twice daily.

Gel (Clindagel), foam (Evoclin): Apply once daily.

Bacterial vaginosis

Bacterial vaginosis:

Note: Treatment is generally not warranted for patients who are asymptomatic. When treatment is given, the 7-day regimen is preferred (Ref).

2% cream (Cleocin): Intravaginal: One applicatorful (5 g containing ~100 mg clindamycin) once daily at bedtime for 7 days (Ref).

2% cream (Clindesse) (alternative agent): Intravaginal: One applicatorful (5 g containing ~100 mg clindamycin) once as a single dose (Ref).

2% gel (Xaciato) (alternative agent): Intravaginal: One applicatorful (5 g containing 100 mg clindamycin) once as a single dose (Ref).

100 mg suppository (alternative agent): Intravaginal: One suppository once daily at bedtime for 3 days (Ref).

Hidradenitis suppurativa

Hidradenitis suppurativa (off-label use): Solution: Topical: Apply to affected area twice daily (Ref).

Rosacea

Rosacea (off-label use): Lotion: Topical: Apply twice daily to the face (Ref).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.

Topical:

>10%:

Dermatologic: Burning sensation of skin (10% to 11%), desquamation (7% to 11%), erythema of skin (7% to 16%), oily skin (1% to 18%), pruritus (7% to 11%)

Local: Local dryness of skin (application site: 1% to 23%)

1% to 10%:

Local: Application-site burning (6%), application-site pruritus (1%)

Nervous system: Headache (3%)

Intravaginal:

>10%: Genitourinary: Vaginitis (≤11%, including trichomonal vulvovaginitis [1%], vaginal discharge [<1%], vaginal infection [<1%], vulvovaginal disease [vulvovaginal burning, vulvovaginal discomfort, vulvovaginal dryness, vulvovaginal erythema, vulvovaginal irritation, vulvovaginal pruritus: ≤6%], vulvovaginitis [4% to 6%]), vulvovaginal candidiasis (2% to 17%)

1% to 10%:

Gastrointestinal: Constipation (2%)

Genitourinary: Urinary tract infection (2%), vaginal pain (2%)

Infection: Candidiasis (≤3%), fungal infection (≤1%)

Nervous system: Headache (7%)

Neuromuscular & skeletal: Back pain (5%)

<1%:

Dermatologic: Cutaneous candidiasis, erythema of skin, maculopapular rash, pruritic rash, pruritus, skin rash, urticaria

Endocrine & metabolic: Hyperthyroidism, intermenstrual bleeding, menstrual disease

Gastrointestinal: Abdominal cramps, abdominal pain, diarrhea, dysgeusia, dyspepsia, flatulence, halitosis, nausea, vomiting

Genitourinary: Dysmenorrhea, dysuria, endometriosis, pelvic pain, uterine hemorrhage (including abnormal uterine bleeding), vaginal discomfort, vaginal dryness, vaginal irritation, vulvitis

Hypersensitivity: Hypersensitivity reaction

Infection: Bacterial infection

Local: Application-site erythema (vaginal)

Nervous system: Dizziness, fatigue, pain, vertigo

Renal: Flank pain, pyelonephritis

Respiratory: Epistaxis

Miscellaneous: Fever

Postmarketing (any formulation):

Dermatologic: Contact dermatitis, folliculitis, seborrhea, skin irritation, skin pain

Gastrointestinal: Bloody diarrhea, Clostridioides difficile colitis, colitis, hematochezia

Genitourinary: Vaginal hemorrhage

Local: Application-site rash, local swelling (vaginal)

Ophthalmic: Eye pain

Contraindications

Hypersensitivity to clindamycin, lincomycin, or any component of the formulation; history of antibiotic-associated colitis, regional enteritis, ulcerative colitis.

Warnings/Precautions

Concerns related to adverse effects:

• Colitis: Use may result in fungal or bacterial superinfection, including Clostridioides difficile-associated diarrhea (CDAD); CDAD has been observed >2 months postantibiotic treatment. Discontinue drug if significant diarrhea, abdominal cramps, or passage of blood and mucus occurs.

• Superinfection: The use of clindamycin may result in the overgrowth of nonsusceptible organisms, particularly yeasts, in the vagina. Treatment-related moniliasis and vaginitis have been reported.

Special populations:

• Atopic patients: Use with caution in atopic patients.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

• Topical foam: Topical foam may cause irritation especially when used with abrasive, desquamating or peeling agents; avoid contact with eyes, mouth, lips, mucous membranes, or broken skin.

• Topical pledget or solution: Topical pledget and topical solution contain an alcohol base and may cause eye irritation or burning. Rinse with cool tap water if product comes in contact with mucous membranes, abraded skin, or eyes. Use caution when applying near mouth (unpleasant taste).

• Vaginal products: May weaken condoms, or contraceptive diaphragms; barrier contraceptives are not recommended concurrently or for 3 to 7 days (depending on the product) following treatment. Avoid vaginal intercourse or use of other vaginal products (eg, douches, tampons) during therapy (Cleocin, Clinedess, Xaciato) and for 3 days after therapy (Xaciato). Vaginal cream contains ingredients that may cause eye burning and irritation; rinse with cool tap water if product comes in contact with the eyes.

Other warnings/precautions:

• Appropriate use: Acne: American Academy of Dermatology (AAD) acne guidelines recommend clindamycin (topical) be used in conjunction with other therapies (not as monotherapy) due to the risk of bacterial resistance. If given for mild acne, clindamycin (topical) should be used in combination with benzoyl peroxide. If given for moderate to severe acne, it should be used in combination with a topical retinoid or systemic antibiotic agent (AAD [Zaenglein 2016]).

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, Vaginal, as phosphate [strength expressed as base]:

Cleocin: 2% (40 g) [contains benzyl alcohol]

Clindesse: 2% (5 g) [contains disodium edta, methylparaben, propylparaben]

Generic: 2% (40 g)

Foam, External, as phosphate [strength expressed as base]:

Clindacin: 1% (100 g) [contains cetyl alcohol, propylene glycol]

Evoclin: 1% (50 g [DSC], 100 g [DSC]) [contains alcohol, usp, cetyl alcohol, propylene glycol]

Generic: 1% (50 g, 100 g)

Gel, Vaginal:

Xaciato: 2% (8 g) [contains benzyl alcohol]

Gel, External, as phosphate [strength expressed as base]:

Cleocin-T: 1% (30 g) [contains methylparaben, propylene glycol]

Clindagel: 1% (75 mL) [contains methylparaben, polyethylene glycol (macrogol), propylene glycol]

Generic: 1% (30 g, 60 g, 75 mL)

Kit, External, as phosphate [strength expressed as base]:

Clindacin ETZ: 1% [contains cetyl alcohol, isopropyl alcohol, propylene glycol]

Clindacin Pac: 1% [DSC] [contains cetyl alcohol, isopropyl alcohol, propylene glycol]

Lotion, External, as phosphate [strength expressed as base]:

Cleocin-T: 1% (60 mL) [contains cetostearyl alcohol, methylparaben]

Generic: 1% (60 mL)

Solution, External, as phosphate [strength expressed as base]:

Generic: 1% (30 mL, 60 mL)

Suppository, Vaginal, as phosphate [strength expressed as base]:

Cleocin: 100 mg (3 ea)

Swab, External, as phosphate [strength expressed as base]:

Clindacin ETZ: 1% (60 ea) [contains isopropyl alcohol, propylene glycol]

Clindacin-P: 1% (69 ea) [contains isopropyl alcohol, propylene glycol]

Generic: 1% (60 ea)

Generic Equivalent Available: US

May be product dependent

Pricing: US

Cream (Cleocin Vaginal)

2% (per gram): $2.17

Cream (Clindamycin Phosphate Vaginal)

2% (per gram): $2.72 - $3.26

Cream (Clindesse Vaginal)

2% (per gram): $33.40

Foam (Clindacin External)

1% (per gram): $5.59

Foam (Clindamycin Phosphate External)

1% (per gram): $4.80 - $6.93

Gel (Clindagel External)

1% (per mL): $28.44

Gel (Clindamycin Phosphate External)

1% (per gram): $0.80 - $3.46

Gel (Xaciato Vaginal)

2% (per gram): $22.50

Kit (Clindacin ETZ External)

1% (per each): $802.57

Lotion (Cleocin-T External)

1% (per mL): $2.34

Lotion (Clindamycin Phosphate External)

1% (per mL): $1.92 - $2.40

Solution (Clindamycin Phosphate External)

1% (per mL): $0.33 - $1.36

Suppository (Cleocin Vaginal)

100 mg (per each): $73.50

Swab (Clindacin ETZ External)

1% (per each): $13.38

Swab (Clindacin-P External)

1% (per each): $12.26

Swab (Clindamycin Phosphate External)

1% (per each): $0.84

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, Vaginal, as phosphate [strength expressed as base]:

Dalacin Vaginal: 2% (40 g) [contains benzyl alcohol, propylene glycol]

Solution, External, as phosphate [strength expressed as base]:

Clinda-T: 1% ([DSC]) [contains isopropyl alcohol, propylene glycol]

Dalacin T: 1% ([DSC]) [contains alcohol, usp, propylene glycol]

Generic: 1% (30 mL, 60 mL)

Administration: Pediatric

Intravaginal: Do not use for topical therapy, instillation in the eye, or oral administration. Wash hands prior to use.

Cream: Fill applicator with cream, then insert into vagina as far as possible without causing discomfort; expel cream. Use each disposable applicator only once; discard applicator after use.

Gel: Not for ophthalmic, dermal, or oral use. Use applicator for insertion.

Suppository: Remove from packaging; if applicator is used for administration, place suppository into applicator and insert applicator into vagina as far as possible without causing discomfort and expel suppository. Patient should lie down after administration to minimize leakage. Wash applicator with soap and water.

Topical: For dermal topical use only. Do not use intravaginally; instill in the eye, or administer orally. Avoid contact with eyes, mouth, lips, mucous membranes, or broken skin.

Foam: Before applying foam, wash affected area with mild soap, then dry. Remove cap, hold can at an upright angle, and dispense foam directly into the cap or onto a cool surface; do not dispense foam directly onto hands or face (foam will melt upon contact with warm skin). If can is warm or foam is runny, run can under cold water. Use fingertips to pick up small amounts of foam and gently massage into affected area until foam disappears. Wash hands after applying. Avoid fire, flame, or smoking during or immediately following application.

Gel, pledget, solution: Solution/pledget contains an alcohol base and if inadvertent contact with mucous membranes occurs, rinse with liberal amounts of water. Remove pledget from foil immediately before use; discard after single use. May use more than one pledget for each application to cover area.

Lotion: Shake well immediately before use; apply topically.

Administration: Adult

Intravaginal:

Cream: Insertion with the applicator should be as far as possible into the vagina without causing discomfort.

Gel: Not for ophthalmic, dermal, or oral use. Use applicator for insertion.

Suppository: Remove from packaging prior to use. If applicator is used for administration, insertion should be as far as possible into the vagina without causing discomfort; wash applicator after each use. Patient should lie down after administration to minimize leakage.

Topical:

Foam: Dispense directly into cap or onto a cool surface; do not dispense directly into hands or face (foam will melt on contact with warm skin). Wash skin with mild soap and allow to fully dry. Apply in small amounts to face using fingertips and gently massage into affected areas until foam disappears. Avoid contact with eyes, mouth, lips, mucous membranes, or broken skin.

Gel: Avoid contact with eyes.

Lotion: Shake well immediately before using.

Solution or pledget: Avoid contact with eyes, mouth or other mucous membranes; solution/pledget contains an alcohol base and if inadvertent contact with mucous membranes occurs, rinse with liberal amounts of water. Remove pledget from foil immediately before use; discard after single use. May use more than one pledget for each application to cover area.

Storage/Stability

Cream: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.

Foam: Store at 20°C to 25°C (68°F to 77°F). Avoid fire, flame, or smoking during or immediately following application. Do not puncture or incinerate container. Do not expose to heat or store at temperatures >49°C (120°F).

Gel: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.

Clindagel: Do not store in direct sunlight.

Xaciato: Excursions are permitted to 15°C to 30°C (59°F to 86°F).

Lotion: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.

Pledget: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.

Suppository: Store at 25°C (77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Avoid heat >30°C (86°F) and high humidity.

Topical solution: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.

Use

Topical: Foam, gel, lotion, pledget, solution: Treatment of acne vulgaris (FDA approved in ages ≥12 years and adults).

Vaginal: Treatment of bacterial vaginosis in the following ages:

Cleocin Ovules, Clindesse Vaginal Cream: FDA approved in postmenarchal adolescents and adults.

Cleocin Vaginal Cream: FDA approved in adults.

Xaciato Gel: FDA approved in ages ≥12 years and adults.

Note : Approved ages and uses for generic products may vary; consult labeling for specific information.

Medication Safety Issues
Sound-alike/look-alike issues:

Cleocin may be confused with bleomycin, Clinoril, Cubicin, Lincocin

Clindamycin may be confused with clarithromycin, Claritin, vancomycin

Clindesse may be confused with Clindets

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Erythromycin (Systemic): May diminish the therapeutic effect of Clindamycin (Topical). Management: Consider avoiding the concomitant use of systemic erythromycin and topical clindamycin when treating acne vulgaris. This recommendation does not appear to apply to intravaginal use of clindamycin for the treatment of bacterial vaginosis. Risk D: Consider therapy modification

Erythromycin (Topical): May diminish the therapeutic effect of Clindamycin (Topical). Management: Consider avoiding use of topical erythromycin and topical clindamycin at the same application site when treating acne vulgaris. This recommendation does not appear to apply to intravaginal use of clindamycin for the treatment of bacterial vaginosis. Risk D: Consider therapy modification

Neuromuscular-Blocking Agents: Clindamycin (Topical) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Reproductive Considerations

Some vaginal products contain mineral oil which may weaken condoms or contraceptive diaphragms. Therefore, use of these products are not recommended for birth control during therapy or for 3 to 7 days (depending on the product) following treatment.

Pregnancy Considerations

Clindamycin crosses the placenta following oral and parenteral dosing (Philipson 1973; Weinstein 1976). The amount of clindamycin available systemically is less following topical and vaginal application than with IV or oral administration.

Various clindamycin vaginal products are available for the treatment of bacterial vaginosis. Recommendations for use in pregnant patients vary by product labeling. Current guidelines note that the same oral or vaginal regimens used in nonpregnant patients may be used during pregnancy, including oral or vaginal clindamycin (CDC [Workowski 2021]).

If treatment for acne is needed during pregnancy, topical clindamycin may be considered if an antibiotic is needed. To decrease systemic exposure, pregnant women should avoid application to inflamed skin for long periods of time, or to large body surface areas (Kong 2013).

Monitoring Parameters

Observe for changes in bowel frequency.

Mechanism of Action

Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Topical solution or foam, phosphate: Minimal; Vaginal cream, phosphate: ~5%; Vaginal suppository, phosphate: ~30%

Metabolism: Hepatic; forms metabolites (variable activity); Clindamycin phosphate is converted to clindamycin HCl (active)

Half-life elimination: Vaginal cream: 1.5 to 2.6 hours following repeated dosing; Vaginal suppository: 11 hours (range: 4 to 35 hours, limited by absorption rate)

Time to peak, serum: Vaginal cream: ~10 to 14 hours (range: 4 to 24 hours); Vaginal suppository: ~5 hours (range: 1 to 10 hours)

Excretion: Urine (<0.2% with topical foam and solution)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Dalacin | Dalacin c | Dalacin t | Medacin t | Yenlip;
  • (AR) Argentina: Acnestop | Clindacin | Clindamicina | Clindamicina Biol | Clinfol | Clintopic | Dalacin crema vaginal | Dalacin Ovulos | Front | Torgyn;
  • (AT) Austria: Dalacin | Zindaclin;
  • (AU) Australia: Clindamycin | Clindatech | Dalacin t | Dalacin v;
  • (BD) Bangladesh: Cleocin | Clindacin | Clindax | Clinex | Daclin;
  • (BE) Belgium: Dalacin | Dalacin Vaginal | Yenlip | Zindaclin;
  • (BF) Burkina Faso: Aclin;
  • (BG) Bulgaria: Clindavasin v | Dalacin;
  • (BR) Brazil: Anaerocid | Clinagel | Clindacne | Dalacin v | Fosfato de Clindamicina;
  • (CH) Switzerland: Dalacin v;
  • (CI) Côte d'Ivoire: Aclin;
  • (CL) Chile: Clidan | Clidets | Clinacnyl | Cluvax | Dalacin Ovulos | Dalacin t | Dalacin v | Dermabel | Divanon;
  • (CN) China: Da lin | Yan le;
  • (CO) Colombia: Bexon | Cleocin t | Clidets | Clindamicina | Clindana | Dalacin v | Damicine | Damiclin v | Euroclin V | Gyno baclin | Infex | Nexoclin | Trexen;
  • (CZ) Czech Republic: Dalacin | Dalacin c | Dalacin t;
  • (DE) Germany: Basocin | Clindamycin aristo | Sobelin | Zindaclin;
  • (DO) Dominican Republic: Afuxclin | Andi vagil plus | Clavel | Clidax | Clinda | Clindamicin | Clindamicina | Clindaris | Clindavic | Clinfol | Cliofar | Cutaclin | Dalacin v | Euroclin | Gynobiotic | Vagibiotic;
  • (EC) Ecuador: Clindacin | Clindamicina | Clindamicina mk | Clindarol | Clindazin | Dalacin v | Divanon | Euroclin | Euroclin V | Ovucin | Vioclin;
  • (EE) Estonia: Climycen | Dalacin c | Dalacin t | Dalacin v | Sobelin | Vagicin;
  • (EG) Egypt: Chemocin | Chenaromita | Clinda sol | Clindacine | Clindaval | Clindavert | Clinocid | Dalacin | Feminaxclind | Utoclind | Vagiclind | Vimodame;
  • (ES) Spain: Clindamicina Aristo | Clinwas | Dalacin;
  • (ET) Ethiopia: Medacin t | Tidact;
  • (FI) Finland: Dalacin;
  • (FR) France: Zindacline;
  • (GB) United Kingdom: Dalacin | Dalacin t | Zindaclin;
  • (GR) Greece: Botamycin n | Climycen | Clindagel | Clindamycin target | Esteria | Fouch | Toliken | Vagiclin | Veldom | Velkaderm | Yenlip | Ygielle;
  • (HK) Hong Kong: Barsueli | Bittle | Bosamin | Claribel | Clindamycin | Clinex | Clingene-t | Clinmax | Cormic | Dalacin t | Eurocin a | Eurotech | Fourcas | Jepster | Kolincin | Lazer | P s d | Pansaric | Pasto | Ramiton | Royalsense | T3 Mycin | Vitara Clinda | Zanifar | Zindaclin;
  • (HR) Croatia: Dalacin | Klimicin V;
  • (HU) Hungary: Dalacin | Dalacin t | Zindaclin;
  • (ID) Indonesia: Cindala | Clidacor | Clinika | Clinium | Daclin acne | Dalacin t | Mediklin | Opiclam;
  • (IE) Ireland: Dalacin | Dalacin t | Zindaclin;
  • (IL) Israel: Dalacin | Zindaclin;
  • (IN) India: Acleen | Aclind | Acloderm | Acne C | Acneclin | Acneris | Acnethro c | Aknarial | Allyte | Clear | Cleargel | Clencin | Clenz | Cliface | Cligel | Climple | Clinagel | Clincent | Clincin | Clincitop | Clincure | Clindac-a | Clinderm | Clindot | Clindy | Clingard | Clinizex | Clinka | Clinlup | Clinmax | Clinof | Clinpeu | Clinred | Clinzit | D'Acne | Erytop | Klinspec | Klynx | Lupin's pim off | Mimosee | Seaglow;
  • (IT) Italy: Cleocin | Clindamicina same | Clindax | Dalacin t | Zindaclin;
  • (JO) Jordan: Clindacin | Clinimycin T | Dalacin c | Dalacin t | Fouch;
  • (JP) Japan: Clindamycin | Clindamycin Dk | Clindamycin Kracie | Clindamycin phosphate Iwaki | Dalacin t;
  • (KE) Kenya: Clincin | Clindabiox | Clindar t | Clindar v | Pip off;
  • (KR) Korea, Republic of: Cleand_all | Cleocin | Dongin epigel | Zindaclin;
  • (KW) Kuwait: Dalacin | Dalacin c | Dalacin t | Medacin t | Vagiclind;
  • (LB) Lebanon: Cliniderm | Clinimycin T | Dalacin c | Danalli | Medacin t | Zindaclin;
  • (LT) Lithuania: Dalacin | Sobelin | Zindaclin;
  • (LU) Luxembourg: Dalacin | Yenlip | Zindaclin;
  • (LV) Latvia: Dalacin | Dalacin t;
  • (MX) Mexico: Aktufoam | Biodaclin | Bredafur | Clidets | Clindamicin | Clindamicina | Clindamicina Rayere | Clintopic | Cliran | Codixil | Cutaclin | Dalacin t | Dalacin v | Dalatina | Dalatina t | Dalatina V | Feisclin | Periplum | Sunoplex V | Trexen;
  • (MY) Malaysia: C mycin | Dalacin t | Dalacin v | T3 Mycin | Tidact | Zindaclin;
  • (NL) Netherlands: Clindamycine | Dalacin | Dalacin t;
  • (NO) Norway: Dalacin | Sobelin;
  • (NZ) New Zealand: Dalacin t | Dalacin v;
  • (PE) Peru: Clindacin-v | Clindamax | Clindamicina | Clindess | Clindox | Clinfol | Clixdin | Cutaclin | Dalacin t 1% | Dalacin v | Damiciclin | Euroclin V | Nexoclin | Plenaliv;
  • (PH) Philippines: Akneclin | Clindamycin | Clinderm | T3 Mycin;
  • (PK) Pakistan: Abwo | Acnesafe | Acsolve | Bacnil v cream | C mycin | Calinax | Ceda v | Clidavix | Clin v | Clinacin | Clinagel | Clinbet | Clincin | Clinco | Clinda derm | Clinda skin | Clinda V | Clindacef v | Clindacin | Clindamax | Clindanor | Clindasol | Clindopax | Clinmax | Clinxer V | Clycin t | Clycin-v | Dalacin t | Dalacin v | Daymac | Daymac vgl | Gynacin | Uniclin | Vagibact | Veclin;
  • (PL) Poland: Clindacne | Clindavag | Dalacin | Dalacin t | Klindacin t | Normaclin | Symbactin | Zindaclin;
  • (PR) Puerto Rico: Cleocin | Cleocin t | Clindagel | Clindamax | Clindesse | Evoclin;
  • (PT) Portugal: Dalacin v | Zindaclin;
  • (PY) Paraguay: Clinfol | Divanon | Polipai | Sesil | Vioclin;
  • (QA) Qatar: Cleocin Phosphate | Clindacin T | Clinimycin T | Dalacin Ovule | Dalacin T | Dalacin V | Derma-T | Medacin T | Vagiclind | Yenlip;
  • (RO) Romania: Ovyx;
  • (RU) Russian Federation: Clindacin | Clindacin prolong | Clindagel | Clindamycin | Clindatop | Clindovit | Clines | Dalacin | Dalacin t;
  • (SA) Saudi Arabia: Clindasol | Clinimycin T | Dalacin t | Derma-t | Medacin t;
  • (SE) Sweden: Dalacin | Klindamycin evolan;
  • (SG) Singapore: Clindagel | Dalacin t | T3 Mycin;
  • (SI) Slovenia: Dalacin | Dalacin t | Klimicin T | Klimicin V;
  • (SK) Slovakia: Dalacin | Dalacin c | Dalacin t;
  • (TH) Thailand: Acny t | Cedelin | Chinacin-t | Clindacne | Clindalin | Clindaman | Klinna | Todacin | Tomei clindai | Vitara Clinda;
  • (TR) Turkey: Cleocin;
  • (TW) Taiwan: Aledo | B.B | Cd | Chyndacin | Clear | Clearcin | Cleocin | Cleocin t | Cleodacin | Clinda | Clindamycin | Cliner | Clingene-t | Dalcine | Demaclean | Dermalean | Glinda | Kolincin | Libido | Royalsense | Shuli Qing | Zindaclin;
  • (UA) Ukraine: Banbakt | Dalacin | Dalacin t | Vagicin;
  • (UG) Uganda: Clycin-v | Vagibact;
  • (UY) Uruguay: Clidan | Clindacin | Clintopic | Dalacin v | Vioclin;
  • (VE) Venezuela, Bolivarian Republic of: Clidets | Clindacin | Clindamicina | Clinfol | Dalacin | Klifer;
  • (VN) Viet Nam: Azaroin;
  • (ZA) South Africa: Dalacin t | Dalacin vc;
  • (ZM) Zambia: C mycin | Pip off
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  3. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  4. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325-328. [PubMed 6347922]
  5. Cleocin T topical gel, lotion, and solution (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; December 2019.
  6. Cleocin T topical solution (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; November 2017.
  7. Cleocin vaginal cream (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; March 2020.
  8. Cleocin vaginal cream (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; August 2021.
  9. Cleocin vaginal cream (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; May 2022.
  10. Cleocin vaginal suppository (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; March 2020.
  11. Cleocin vaginal suppository (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn; July 2022.
  12. Clindacin (clindamycin) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals, Inc; April 2022.
  13. Clindacin ETZ (clindamycin) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals Inc; October 2016.
  14. Clindagel (clindamycin) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; January 2020.
  15. Clindamycin Phosphate (topical) [prescribing information]. Durham, NC: Encube Ethicals, Inc; January 2020.
  16. Clindamycin phosphate vaginal cream [prescribing information]. Peapack, NJ: Greenstone LLC; May 2022.
  17. Clinda-T (clindamycin) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; February 2022.
  18. Clindesse (clindamycin) vaginal cream [prescribing information]. Allegan, MI: Padagis; November 2023.
  19. Clindets pledgets (clindamycin solution) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; October 2016.
  20. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131 Suppl 3:S163-186. [PubMed 23637225]
  21. Evoclin (clindamycin) foam [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; April 2018.
  22. Faro S, Skokos CK; Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol. 2005;13(3):155-160. doi:10.1080/10647440500148321 [PubMed 16240515]
  23. Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 3, 2022.
  24. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  25. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. [PubMed 22236226]
  26. Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs. 2013;73(8):779-787. [PubMed 23657872]
  27. Mauck C, Hillier SL, Gendreau J, et al. Single-dose, bioadhesive clindamycin 2% gel for bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2022;139(6):1092-1102. doi:10.1097/AOG.0000000000004805 [PubMed 35675606]
  28. Philipson A, Sabath LD, and Charles D, "Transplacental Passage of Erythromycin and Clindamycin," N Engl J Med, 1973, 288(23):1219-21. [PubMed 4700555]
  29. Refer to the manufacturer's labeling.
  30. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  31. Weinstein AJ, Gibbs RS, and Gallagher M, "Placental Transfer of Clindamycin and Gentamicin in Term Pregnancy," Am J Obstet Gynecol, 1976, 124(7):688-91. [PubMed 943947]
  32. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32(1):65-67. [PubMed 8425809]
  33. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
  34. World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.
  35. Xaciato (clindamycin) [prescribing information]. Jersey City, NJ: Organon LLC; December 2023.
  36. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022. [PubMed 26897386]
Topic 15954 Version 500.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟